🟢 Neurosense Therapeutics is trading 12% up in pre-market after HC Wainwright initiated Buy-rated coverage

Neurosense Therapeutics is trading 11.93% up at $0.46 after HC Wainwright & Co. initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price target.

• On August 31, the company announced a redesigned, capital-efficient PrimeC development strategy for ALS.
• The strategy includes an accelerated path toward potential regulatory submission.
• Broader markets were mixed, so the company-specific catalyst appears to be the primary driver.